Sources
BowTiedBiotech 🧪🔬🧬
$BTAI ripped +20% pre but already faded to -4%. Classic sell-the-news. Serenity-at-Home hit exactly what was needed, but PEC deltas (~13–15%) were in-line with Serenity I/II, not a breakout. Traders who piled in for a “blowout” read quickly flipped, and thin float amplified the https://t.co/B2EVvc2nIF
Life Science Report UPDATE -- BioXcel Therapeutics Announces SERENITY At-Home Pivotal Phase 3 Safety Trial Met its Primary Endpoint in Support of sNDA Submission for Label Expansion of IGALMI® $BTAI https://t.co/tNUPDSS61W
- Life Science Report
Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for IgA Nephropathy $VOR https://t.co/YR0NpQPHRX
Additional media
Loading...
